To: BUSINESS EDITORS
Contact: Patty Eisenhaur of Watson Pharmaceuticals, Inc., 1-951-
493-5611
Related Results
Biovail Announces Receipt Of An Approvable Letter For Wellbutrin XL.
IMS INSIGHTS Rx SALES SLOWING
Biovail shares crash after motorway accident puts dent in revenues.
Biovail Corporation: FDA Approves Wellbutrin XL; New, Once-Daily Antidepressa… amoxicillin.
The Collected Works of Paul Lingel
CORONA, Calif., June 13 /PRNewswire-FirstCall/ — Watson
Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical
company, announced that it has received final approval from the
United States (U.S.) Food and Drug Administration on its Abbreviated
New Drug Application (ANDA) for bupropion hydrochloride extended-
release tablets, 300 mg. Bupropion hydrochloride extended-release is
the generic equivalent to GlaxoSmithKline’s Wellbutrin XL(R) tablets,
which is indicated for the treatment of …
Read the rest of this article with a Free Trial at HighBeam Research.